688809-04-3

Upstream product

• 913375-43-6 3-(3-chloro-8-methoxymethoxy-quinoxalin-2-yl)-2-fluoro-benzoic acid methyl ester 
• 67-56-1 methanol 
• 913375-41-4 3-ethoxyoxalyl-2-fluoro-benzoic acid methyl ester 
• 913375-42-5 3-[8-(tert-butyl-dimethyl-silanyloxy)-3-oxo-3,4-dihydro-quinoxalin-2-yl]-2-fluoro-benzoic acid methyl ester 
• 348-52-7 1-Fluoro-2-iodobenzene 
• 447464-03-1 2-fluoro-3-iodobenzoic acid 
• 1260830-14-5 methyl 2-fluoro-3-iodobenzoate 
• 688808-15-3 C₁₉H₁₆BrFN₂O₅ 

Downstream Products

• 913375-44-7 2-fluoro-3-(3-methoxy-8-methoxymethoxy-quinoxalin-2-yl)-benzoic acid 
• 913375-45-8 N'-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-N'-[2-fluoro-3-(3-methoxy-8-methoxymethoxy-quinoxalin-2-yl)-benzoyl]-hydrazinecarboxylic acid allyl ester 

Relevant academic research and scientific papers

Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure

The design of a novel series of cyclin-dependent kinase (CDK) inhibitors containing a macrocyclic quinoxaline-2-one is reported. Structure-based drug design and optimization from the starting point of diarylurea 2, which we previously reported as a modera

NOVEL QUINOXALINE DERIVATIVES

A quinoxalinone derivative of the formula (I): or a pharmaceutically acceptable salt or ester thereof, wherein; ???X is NH, S or the like; ???Y is O or the like; ???the partial structure is, for example, the formula: ???B1, B2, ....., Bn-1 and Bn, (in which n is 4 , 5 or 6) are each independently CH, N or the like; ???B'1, B'2, ....., B'n-1 and B'n (in which n is 4, 5 or 6) are each independently hydrogen or the like; and ???R is hydrogen, lower alkyl or the like.